12 just out . april 17, 1998

APRIL SHOWERS... BRING SALE FLOWERS!

PRESENTING A SPRING SEMINAR WITH MATT WOOD, AIFD TUESDAY, APRIL 21, 7-9 PM **\$15 PER PERSON RESERVATIONS REQUIRED**



Internationally known floral designer, consultant and educator. Matt shares his expertise for vibrant floral designs and "bow to" ideas using clear resins and stunning silk florals.



-Emily Simon Out with Clout

Emily Simon and Tracey Cordes, proud members of our community specializing in criminal defense.

to criminal defense

never on the fence when it comes

Misdemeanor felony, traffic, & DUII actions in state, federal, & juvenile courts civil forfeitures, & administrative actions

(503) 241-1553

You work hard to get to the top so you can enjoy

NATIONAL news

TRYING TIMES

The Portland area is one of the sites for an AmFAR clinical study of combination drug therapy for hepatitis C and HIV by Bob Roehr

he American Foundation for AIDS Research has begun recruitment for the first clinical trial of combination therapy for hepatitis C among those who are also HIVpositive. The 18-month study will involve 200 patients at 20 sites around the nation, including Portland.

Protease combination therapy has dramati-

cally beaten back HIV for many, but that success has allowed time for more slowly developing medical conditions, such as hepatitis C, to emerge.

This second viral infection attacks the liver, scarring it and reducing liver function over the course of decades. Liver damage can make it harder to metabolize certain drugs, including protease inhibitors. It can ultimately lead to complete liver failure and death.

Some people living with HIV/AIDS who carry hepatitis C may not even know they have it. Until recently there was little

effective therapy, so many doctors didn't even bother to screen for the hepatitis C virus. Furthermore, the standard screening test misses


as many as half of the hepatitis C cases among those with HIV. therapy has dramatically

Many people with hepatitis C were infected through tainted blood products utilized prior to a screening program initiated in 1990.

Today, new infections are likely to come through sharing needles, cocaine straws, and blood during rough sex. about 50 percent of cases. The combination has been submitted to the FDA for market approval.

So far, none of the trials of interferon and ribavirin have dealt with HIV-positive people. But anecdotal evidence suggests disease progression and reaction to treatment will be similar whether one is infected only with hepatitis C virus or coinfected with HIV.

AmFAR brought physicians participating in



Protease combination

beaten back HIV for

many, but that success

has allowed time for

more slowly developing

will receive interferon and a placebo, explained Kevin Frost, director of clinical research for AmFAR. The trial will measure hepatitis C viral load at several points during the regimen, as well as six months after it is complet-


The 18-month study

ed, to see if there is sustained viral suppression. Volunteers must have any HIV drug regimen

stabilized at least four weeks prior to beginning this trial. Part of the initial screening process is

> a liver biopsy-a potentially painful procedure-to determine what, if any, liver scarring is present.

Participants will be taught to inject interferon under their skin, much as a diabetic does with insulin. Injections will be administered at least three times a week, or perhaps daily, for the duration of the trial.



medical conditions, such Condoms offer protection, and as hepatitis C, to emerge. the risk via oral sex is believed to be very small.

Interferon alpha is currently the only federal Food and Drug Administration-approved therapy for hepatitis C. It brings sustained viral repression in only 20 percent of those who complete the regimen.

A combination adding the synthetic nucleoside ribavirin seems to suppress the virus in

Side effects of interferon range from very mild to severe flulike symptoms and

are often dose-related. Ribavirin is a pill with generally mild side effects. Both can cause anemia and loss of blood platelets.

For further information about the trial, contact Norma Martinez of the Portland-based Research & Education Group at 229-8428.

